Skip to content
Checked.be
Complete company report
Generated 09-08-2026
Active BE 0859.704.565Private limited company

MA-EL RX

Av la Douce Colline 22 ·1420 Braine-l'Alleud, Belgium· 23 yrs active
Sector: Human health (86220)
Conclusion Checked

The computed 12-month bankruptcy probability of MA-EL RX is 0.1% (very low). The 2024 annual accounts show equity of €423k and a net result of €74k. Equity is growing by ~42.6% per year across the filed fiscal years. Its solvency ranks better than 95% of 255 sector peers (fiscal year 2024). The company has been active since 2003 and the Belgian State Gazette contains no insolvency or warning signals.

Based on the State Gazette, CBE and 7 annual accounts.
Key figures
Equity €423k
Net result €74k
Staff (FTE) 0.2
Better than sector 95%
Snowflake analysis 5 axes · computed by Checked
Health93Profitability88Solvency100Growth52Stability100
87 / 100

Exceptional profile, strong across almost every axis.

Health 93
Profitability 88
Solvency 100
Growth 52
Stability 100
Bankruptcy probability (12 mo) Checked model v1 · free
0.1% Very low
0%0,5%1,5%4%10%≥25%
Lower-failure-rate sector −Long track record −Annual accounts: healthy financial profile −

Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?

Risk Assessment rule-based
0 / 100
Low risk
Trust signals 3 signals
Long-established
Founded in 2003, 23 years in business.
No legal incidents
No bankruptcy, reorganisation or interim measure in the Belgisch Staatsblad.
Administratively compliant
No FOD Economie strikeouts (UBO, accounts, address, activity).
Administrative Flags 0 events
No administrative flags
Health barometer FY 2024 · computed
93 / 100 Excellent
050100

Unlock the full score breakdown, per-year score history and the indicative credit limit with Plus.

See plans →
Computed by Checked from NBB filings and Belgian State Gazette signals. Indicative, not credit advice.
Financial overview10 NBB filings
Annual accounts filed on 08-07-2025 with the NBB · fiscal year 2024 · volledig
€0€100k€200k€300kOperating result 2020: €126k€126kNet result 2020: €96k€96kOperating result 2021: €93k€93kNet result 2021: €61k€61kOperating result 2022: €77k€77kNet result 2022: €49k€49kOperating result 2023: €255k€255kNet result 2023: €170k€170kOperating result 2024: €112k€112kNet result 2024: €74k€74k20202021202220232024
Operating resultNet result
Trajectory (indicative)
Projection over 3 fiscal years from the filed annual accounts, not a forecast, the extended trend.
growing Equity: growth of ~42.6%/year over 7 fiscal years, indicative, assuming unchanged policy.
€0€500k€1.00M€1.50M2025: €617k (€583k - €650k)2026: €880k (€846k - €913k)2027: €1.25M (€1.22M - €1.29M)2018: €51k2019: €79k2020: €98k2021: €159k2022: €208k2023: €377k2024: €423k2018201920202021202220232024202520262027
Solid line = filed figures · dashed = extended trend · area = indicative range.
How do we compute this?

The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.

The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.

A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).

Sector comparison
Fiscal year 2024 · NACE 86, Human health · compared within the same schema type (full schema)
Metric This company Sector median Position in the sector
Solvency 93.5% 49.4%
better than 95% of 255 sector peers
Net result €74k €50k
better than 62% of 254 sector peers
Equity €423k €126k
better than 77% of 255 sector peers
Gross operating margin €144k €145k
better than 50% of 250 sector peers
Staff costs €12k €156k
higher than 8% of 114 sector peers
Median and position computed from NBB annual accounts filed by sector peers; own figures from the latest filed accounts.
EBITDA
€131k
-53.2% -34% vs sector
Net profit
€74k
-56.3% -22% vs sector
Cash flow
€93k
-52.4% -42% vs sector
Total assets
€452k
-12.0% -66% vs sector
Equity
€423k
+12.2% -63% vs sector
Working capital
€222k
-7.8% -60% vs sector
Employees (FTE)
0
0.0% -80% vs sector
Staff costs
€12k
+6.8% -75% vs sector
Income taxes
€37k
-54.2% -40% vs sector
Dividends
€28k
+3426.8% -7% vs sector
Debt
€29k
-78.6% -80% vs sector
Debt ≤ 1y
€23k
-49.7% -65% vs sector
Debt > 1y
€1k
-87.3% -99% vs sector
Current ratio
10.70
+70.0% +19% vs sector
Quick ratio
10.70
+70.0% +19% vs sector
Solvency
93.5%
+27.6% +26% vs sector
Debt / equity
0.07
-80.9% -46% vs sector
ROE
17.5%
-61.1% +83% vs sector
ROA
16.4%
-50.3% +83% vs sector
Interest coverage
64.02
-31.4% ≈ vs sector
Figures by fiscal year
Fiscal year2024
Revenue-
EBITDA€131k
Net profit€74k
Cash flow€93k
Staff costs€12k
Income taxes€37k
Dividends€28k
Total assets€452k
Equity€423k
Debt€29k
of which ≤ 1y€23k
of which > 1y€1k
Working capital€222k
Employees (FTE)0.2
Ratios (computed)
2024
Current ratio10.70
Quick ratio10.70
Working capital ratio49.2%
Solvency93.5%
Debt / equity0.07
Long-term debt ratio0.00
Interest coverage64.02
Gross margin-
Net margin-
ROA16.4%
ROE17.5%
EBITDA margin-
Days sales outstanding-
Days payable outstanding-
Inventory turnover-
Days inventory (DSI)-
Balance-sheet composition 2024
Full annual accounts
Filed balance sheet and income statement, exactly as deposited with the NBB.
Line item Code2024
Balance sheet, Assets
TOTAL ASSETS 20/58€452k
Fixed assets 21/28€207k
Tangible fixed assets 22/27€27k
Financial fixed assets 28€180k
Current assets 29/58€245k
Amounts receivable within one year 40/41€16k
Cash & bank 54/58€181k
Balance sheet, Equity & liabilities
TOTAL EQUITY & LIABILITIES 10/49€452k
Equity 10/15€423k
Contributions / capital 10/11€12k
Reserves 13€403k
Accumulated profits (losses) 14€7k
Amounts payable 17/49€29k
Amounts payable after one year 17€1k
Amounts payable within one year 42/48€23k
Trade debts payable within one year 44€3k
Income statement
Gross operating margin 9900€144k
Operating result 9901€112k
Financial income 75€1k
Financial charges 65€2k
Result before taxes 9903€112k
Income taxes 67/77€37k
Net result for the period 9904€74k
Result to be appropriated 9905€74k
You're seeing the latest fiscal year only. Unlock 4 prior years (figures + ratios) with a paid plan. See plans →
Ratios computed by Checked.
Directors & mandates 2 directors
Current directors & mandates
  • LORENT Marie
    Director
    State Gazette act 25129685 (13-10-2025)
    Current
    01-10-2025 → present
  • BOUCHE Béatrice Louise Marcelle
    Director
    State Gazette act 23462539 (19-12-2023)
    Current
    19-12-2023 → present
    2 events
    • 19-12-2023 Mandate renewed· Director
    • 19-12-2023 Resigned· Manager
Full appointment history from the Belgian State Gazette. Permanent representatives are shown for corporate directors.
Legal Structure
NACE primary Human health(86220)
Legal form Private limited company(610)
Incorporation16-06-2003
StatusActive
Postal code1420
Establishment units 1 location
Leopold III-laan 5, 1030 Schaarbeek
Medische praktijken
since 20032.233.641.764
Physical sites registered in the Crossroads Bank for Enterprises (CBE).
Real-estate footprint Source: CBE × cadastre

Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.

Brussels 1 (100%)
Parcel (capakey) Region Area Buildings Height / fl.
21904B0398/00G000 Brussels 405 m² 1 · 380 m² 28.2 m · 8 fl.
Methodology
via establishment units: 1
1 of 1 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Updates 12 events

A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.

2025
13-10-2025
State Gazette act Director changes
v3.2
08-07-2025
NBB filing Annual accounts filed
fiscal year 2024 · volledig
2024
26-07-2024
NBB filing Annual accounts filed
fiscal year 2023 · volledig
2023
19-12-2023
State Gazette act Statutes amendment
v3.2
27-07-2023
NBB filing Annual accounts filed
fiscal year 2022 · micro
2022
21-06-2022
NBB filing Annual accounts filed
fiscal year 2021 · micro
2021
17-06-2021
NBB filing Annual accounts filed
fiscal year 2020 · micro
2020
12-06-2020
NBB filing Annual accounts filed
fiscal year 2019 · micro
2019
21-06-2019
NBB filing Annual accounts filed
fiscal year 2018 · micro
2018
28-06-2018
NBB filing Annual accounts filed
fiscal year 2017 · micro
2017
30-06-2017
NBB filing Annual accounts filed
fiscal year 2016 · micro
2016
04-07-2016
NBB filing Annual accounts filed
fiscal year 2015 · volledig
Belgisch Staatsblad, acts 2 acts
All acts · 2 updated 10 months ago
2025
13-10-2025 LORENT Marie appointed as director Director changes
  • LORENT Marie, Bestuurder
Summary: v3.2
Technical details 
{
  "events": [
    {
      "kind": "director_in",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "LORENT Marie",
        "address": null,
        "birth_date": null
      },
      "effective_date": "2025-10-01",
      "evidence_quote": "L\u0027assembl\u00E9e g\u00E9n\u00E9rale d\u00E9cide \u00E0 l\u0027unanimit\u00E9 de nommer au poste d\u0027administrateur Madame LORENT Marie \u00E0 partir du 1er octobre 2025."
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0859.704.565",
    "name_full": "MA-EL RX",
    "legal_form": "SRL"
  }
}
2023
19-12-2023 Articles of association amended Statutes amendment
Summary: v3.2
Technical details 
{
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "statute_change": {
    "name_change": false,
    "seat_change": false,
    "object_change": false,
    "effective_date": "2023-12-13",
    "legal_form_change": false
  },
  "bedrijfsrevisor": null,
  "subject_company": {
    "kbo": "0859.704.565",
    "name_full": "MA-EL-RX",
    "legal_form": "SPRL"
  },
  "signature_regime": "solo",
  "special_mandates": [],
  "governance_change": {
    "admin_delegated_added": []
  }
}
Credit advice verdict per customer and amount

Should this customer buy amount X on invoice? Enter the amount and payment terms, you get an instant GREEN/AMBER/RED verdict, with a suggested ceiling and concrete conditions.

Based on official sources (NBB, CBE, State Gazette). Indicative, not credit advice.
AI due-diligence brief Checked AI

Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.

Coming soon
The brief is drafted by our AI model at Anthropic in the US, from this dossier's public data. Nothing that identifies you is sent along and we do not keep the brief. Indicative, not legal or investment advice. How it works
Company registry (CBE) Crossroads Bank
Activities
Praktijken van specialisten86220Activiteiten van medisch specialisten86220
Primary activity highlighted.
Names & trade names
Legal nameFR MA-EL RX
Registered office
Av la Douce Colline 22
1420 Braine-l'Alleud, Belgium
Official data from the Crossroads Bank for Enterprises (CBE). Available for every registered company.
Similar companies Same NACE
Docteur Michel PIRENNE BE 0462.499.364 · Verviers
FYSISCHE GENEESKUNDE EN REVALIDATIE, Dr. BONTE BE 0436.909.477 · Gent
DR. CLAESSENS FRANK BE 0458.738.833 · Maaseik
CABINET MEDICAL DU DOCTEUR LUC PAILLET BE 0464.651.279 · Herve
Docteur Christoph WAGNER BE 0432.567.243 · Eupen
Source: Belgian State Gazette, CBE, NBB · generated via checked.be · indicative